

## Information about ordinary shares of QBiotech Group Limited as at 31 May 2026

### Purpose

This document provides information regarding the ordinary share capital of QBiotech Group Limited (the Company) as of 31 May 2026. It is intended for shareholders and their advisors to understand the Company's share status and recent transactions.

### Information as at 31 May 2026

- The Company had 490,705,471 fully paid ordinary shares on issue.
- The Company's ordinary shares were not listed in an open market as at 31 May 2026 or at any point during the period ended on that date.
- The Company has not performed a formal valuation of the Company as at 31 May 2026.

### Highest price, lowest price and volume of share transfers

To the best of the Company's knowledge, a total of 75,389 shares were transferred in the month of May 2026 with the highest share transfer between unrelated parties during May 2026 being \$0.40 per share and the lowest share transfer between unrelated parties during May 2026 being \$0.33 per share.

### 60 Day weighted average transaction value

From time to time, the Company is required to calculate an estimated market value of the Company's shares for accounting and taxation purposes. The Company uses the weighted average transaction value of off-market share transactions for a period of 60 days leading up to the measurement date to calculate the estimated market value. The calculated value is then analysed against a historic trend and adjusted for any transactions which may have involved distressed sellers or non-arm's length transactions.

The weighted average transaction value of ordinary shares sold during the 60 days leading up to 31 May 2026 was \$0.358 per share.

### One month weighted average transaction value

The Company generally also prepares a one-month weighted average transaction value using the weighted average transaction value of off-market share transactions for the month. The calculated value is then analysed against a historic trend and adjusted for any transactions which may have involved distressed sellers or non-arm's length transactions.

The weighted average transaction value of ordinary shares sold during March 2026 was \$0.358 per share.

### Financial statements

The latest available financial statements are available on the Company's website.

### Disclaimer

This document is not a valuation of ordinary shares in the Company or a valuation of the business conducted by the Company. Where an unlisted ordinary share is held privately by an individual or group of shareholders, applying the appropriate valuation method (or methods) may be complex.

The information in this document is general and does not constitute formal advice. The Company recommends seeking advice from a qualified accountant, professional valuation advisor or otherwise suitably qualified professional if you intend to rely upon any of the information provided for any purpose including accounting or tax purposes.



While the Company tries to ensure that the content of this document is accurate, adequate, and complete, it does not represent or warrant its accuracy, adequacy or completeness. The Company is not responsible for any loss suffered as a result of or in relation to the use of this document. To the extent permitted by law, the Company excludes any liability, including any liability for negligence, for any loss, including indirect or consequential damages arising from or in relation to the use of this document.